Search results
Author(s):
Harry Crijns
,
Elton Dudink
,
Nikki Pluymaekers
Added:
4 years ago
Prof Harry Crijns (Maastricht University Medical Center, Maastricht, NL) discusses the 'Wait-and-See versus Acute Cardioversion trial in Recent-Onset AF patients' with his colleagues Dr Elton Dudink and Dr Nikki Pluymaekers who conducted the trial.
Filmed on site at EHRA 2019 by Radcliffe Cardiology
Questions:
1. What is the rationale for this study?
2. What was the design of the trial?
3…
View more
EHRA 2019: Internal vs. External Electrical Cardioversion of Atrail Arrhythmias in Patients With an…
Author(s):
Jakob Luker
Added:
4 years ago
Video
The European Cardiology Arena - In Brief: A Round-up of Trends, Statistics and Clinical Research
Added:
3 years ago
Article
Author(s):
Tonje A Aksnes
,
Markus P Schneider
,
Sverre E Kjeldsen
,
et al
Added:
3 years ago
The renin–angiotensin system (RAS) has an important role in many cardiovascular diseases, such as hypertension, left ventricular hypertrophy, atherosclerosis and heart failure, and lately its relationship with cardiac arrhythmias has also been investigated.1 Atrial fibrillation is the most frequently occurring sustained cardiac arrhythmia and its prevalence doubles with each advancing decade of…
View more
Author(s):
A John Camm
,
Craig Pratt
,
Silvia Priori
Added:
3 years ago
Atrial fibrillation (AF) is the most common cardiac arrhythmia, having an estimated combined prevalence of 6.8 million in the EU and the US.1,2 It is characterised by unco-ordinated atrial activation followed by the deterioration of mechanical function, which results in disturbances to sinus rhythm and ventricular rate.2 An increased risk of heart failure (HF), thrombo-embolism, cardiomyopathy, a…
View more
Author(s):
Frank Provenier
,
Steven Droogmans
Added:
3 years ago
Atrial fibrillation (AF) is defined as a supraventricular tachycardia with rapid uncoordinated atrial activation, beat-to-beat irregularity and frequently rapid ventricular rate.2 It is the most frequently observed sustained arrhythmia in clinical practice.3 An estimated 12 million individuals in the EU and 2.3–10 million in the US have AF, and these numbers are expected to increase as the age of…
View more
Anders Sjørslev Schmidt
Author
Author(s):
Fernando Worner
,
Cristina Marzo
,
Kristian Rivera
,
et al
Added:
3 years ago
Topic: 1. Clinical Cardiology
Introduction
Universal use of Directs Oral Anticoagulants (DOACs) in non valvular atrial fibrillation (nVAF) is not possible for economic reasons. Therefore, it is mandatory to guarantee their prescription of these drugs in patients theoretically most benefited.
Objectives
To review indications and results of one territorial, prospective and centralized…
View more
The Place of Antiarrhythmic Drugs and Rhythm Control in the Treatment of Atrial Fibrillation
Author(s):
Philippe Chevalier
Added:
3 years ago
Article
Author(s):
Laurent Fauchier
Added:
3 years ago
Hypothetically, 3-hydroxy-3-methylglutaryl co-enzyme A (HMG-CoA) reductase inhibitors (statins) protect against arrhythmias in addition to their well-established secondary prevention benefits against atherosclerotic coronary artery disease. The use of statins has been suggested to protect against atrial fibrillation (AF) in some clinical studies, but remains rather inadequately explored…
View more